Astrazeneca Non-oncology Trial Failure is Unexpected
Dow Jones
Jul 09
0754 GMT - AstraZeneca's negative headline results for its Wainua drug trial are unexpected, analysts at Bernstein say in a note. The U.K. drugmaker said the trial evaluating Wainua for transthyretin amyloid cardiomyopathy, a rare heart disease, didn't meet its primary objective. "We've just spoken to AZN who are extremely and disappointed surprised by this news," the analysts say. "We are too." The company recently doubled the trial size to 1,400 patients to increase the chances of positive, statistically rigorous results on the primary endpoint in the total population, Bernstein says. Shares fall 8.9%. (andrea.figueras@wsj.com)
(END) Dow Jones Newswires
July 09, 2026 03:54 ET (07:54 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.